Skip to main content
Diseases

代谢相关脂肪性肝炎 (MASH)

About this disease

Disease classification：hepatitis; hepatobiliary disorder; digestive system disorder; fatty liver disease; endocrine system disorder; liver disorder

Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis or NASH) is a type of fatty liver disease. It often develops due to a metabolic disorder, such as obesity or diabetes, resulting in a toxic buildup of fat in the liver. It is the most severe form of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as nonalcoholic fatty liver disease or NAFLD).

Standard definition source：MONDO:0007027 metabolic dysfunction-associated steatohepatitis · ontology version 2026-10-06

Applicable models (published, verified)

References

  1. Van Herck Mikhaïl A., Vonghia Luisa, Francque Sven M.. Animal Models of Nonalcoholic Fatty Liver Disease—A Starter’s Guide. Nutrients. 2017.
  2. Kim Kyung Eun, Lee Jaewoong, Shin Hyun Joo, Jeong Eun Ae, Jang Hye Min, Ahn Yu Jeong, An Hyeong Seok, Lee Jong Youl, Shin Meong Cheol, Kim Soo Kyoung, Yoo Won Gi, Kim Won Ho, Roh Gu Seob. Lipocalin‐2 activates hepatic stellate cells and promotes nonalcoholic steatohepatitis in high‐fat diet–fed Ob/Ob mice. Hepatology (Baltimore, Md.). 2023.
  3. Lau Jennie Ka Ching, Zhang Xiang, Yu Jun. Animal models of non‐alcoholic fatty liver disease: current perspectives and recent advances. The Journal of Pathology. 2016.
  4. Sanches Sheila Cristina L., Ramalho Leandra Naira Z., Augusto Marlei Josiele, da Silva Deisy Mara, Ramalho Fernando Silva. Nonalcoholic Steatohepatitis: A Search for Factual Animal Models. BioMed Research International. 2015.
  5. Tripathi Anupriya, Debelius Justine, Brenner David A., Karin Michael, Loomba Rohit, Schnabl Bernd, Knight Rob. The gut-liver axis and the intersection with the microbiome. Nature reviews. Gastroenterology & hepatology. 2018.
  6. Kumar Sudhir, Verma Alok K., Rani Richa, Sharma Akanksha, Wang Jiang, Shah Shimul A., Behari Jaideep, Gonzalez Rosa Salazar, Kohli Rohit, Gandhi Chandrashekhar R.. Hepatic deficiency of augmenter of liver regeneration predisposes to nonalcoholic steatohepatitis and fibrosis. Hepatology (Baltimore, Md.). 2020.
  7. Zhao Xu-Yun, Xiong Xuelian, Liu Tongyu, Mi Lin, Peng Xiaoling, Rui Crystal, Guo Liang, Li Siming, Li Xiaoying, Lin Jiandie D.. Long noncoding RNA licensing of obesity-linked hepatic lipogenesis and NAFLD pathogenesis. Nature Communications. 2018.
  8. Goossens Nicolas, Jornayvaz François R.. Translational Aspects of Diet and Non-Alcoholic Fatty Liver Disease. Nutrients. 2017.
  9. Santhekadur Prasanna K., Kumar Divya P., Sanyal Arun J.. PRECLINICAL MODELS OF NONALCOHOLIC FATTY LIVER DISEASE. Journal of hepatology. 2017.
  10. Yanguas Sara Crespo, Cogliati Bruno, Willebrords Joost, Maes Michaël, Colle Isabelle, van den Bossche Bert, de Oliveira Claudia Pinto Marques Souza, Andraus Wellington, Alves Venâncio Avancini Ferreira, Leclercq Isabelle, Vinken Mathieu. Experimental models of liver fibrosis. Archives of toxicology. 2015.
  11. Riordan Jesse D., Nadeau Joseph H.. Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse. Mammalian Genome. 2014.
  12. Oseini Abdul M., Cole Banumathi K., Issa Danny, Feaver Ryan E., Sanyal Arun J.. Translating scientific discovery: the need for preclinical models of nonalcoholic steatohepatitis. Hepatology international. 2018.
  13. Wu Jian. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma. Oncotarget. 2016.
  14. Bettermann Kira, Hohensee Tabea, Haybaeck Johannes. Steatosis and Steatohepatitis: Complex Disorders. International Journal of Molecular Sciences. 2014.
  15. Liu Yu, Wang Da-Wei, Wang Dan, Duan Bin-Hong, Kuang Hong-Yu. Exenatide Attenuates Non-Alcoholic Steatohepatitis by Inhibiting the Pyroptosis Signaling Pathway. Frontiers in Endocrinology. 2021.
  16. Ibrahim Samar H., Hirsova Petra, Malhi Harmeet, Gores Gregory J.. Animal Models of Nonalcoholic Steatohepatitis: Eat, Delete, and Inflame. Digestive diseases and sciences. 2015.
  17. Wahlang Banrida, Beier Juliane I., Clair Heather B., Bellis-Jones Heather J., Falkner K. Cameron, McClain Craig J., Cave Matt C.. Toxicant-associated Steatohepatitis. Toxicologic pathology. 2012.
  18. Betrapally Naga S, Gillevet Patrick M, Bajaj Jasmohan S. Gut Microbiome and Liver Disease. Translational research : the journal of laboratory and clinical medicine. 2016.
  19. Takakura Kazuki, Oikawa Tsunekazu, Tomita Yoichi, Mizuno Yusuke, Nakano Masanori, Saeki Chisato, Torisu Yuichi, Saruta Masayuki. Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma. World Journal of Gastroenterology. 2018.
  20. Tao Rongya, Stöhr Oliver, Tok Ozlem, Andres-Hernando Ana, Qiu Wei, He Baiyu, Wang Caixia, Grøntved Lars, Burant Charles, Hui Sheng, Lanaspa Miguel A., Stefan Norbert, Copps Kyle D., White Morris F.. Fructose and follistatin potentiate acute MASLD during complete hepatic insulin resistance. Nature Communications. 2025.